 |
14 Products |  |
223 Diseases | | 14 Products |
|
9 Trials |  |
2094 News |  |
| «12345678910111213...1617» |
- | Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Journal: Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model. (Pubmed Central) - Nov 12, 2020
Fenofibrate significantly inhibited the expressions of NF-κB and inflammatory chemokines and reduced oxidative products within diabetic retina. Treatment of fenofibrate might be beneficial to preventing DR progression.
- | Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Review, Journal: Hypouricemia: what the practicing rheumatologist should know about this condition. (Pubmed Central) - Nov 12, 2020
The rheumatologist is considered an expert in the metabolism of urate and its associated pathological conditions. Therefore, specialists must recognize hypouricemia as a biomarker of various pathological and potentially harmful conditions, highlighting the importance of conducting a deeper clinical investigation to reach a more accurate diagnosis and treatment.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARα-inhibition. (Pubmed Central) - Nov 12, 2020
As the peroxisome proliferator - activated receptor alpha (PPARα) agonist, fenofibrate has been widely used to be a good lipid-regulating drug in the clinical application...However, the results in PPARα-/- CNV and keratocytes model were opposite. Our results suggest that keratocytes could promote the expression of VEGFr3 and MMP13, and CNV formation through PPARα downregulation.
- ||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Clinical, P3 data, Journal: A PHASE III STUDY TO EVALUATE SAFETY AND EFFICACY OF FLUTICASONE/FORMOTEROL COMBINATION (FLUTIFORM AEROSOL) IN LONG-TERM ADMINISTRATION (24 WEEKS) IN JAPANESE PEDIATRIC PATIENTS WITH BRONCHIAL ASTHMA (Pubmed Central) - Nov 12, 2020
Our results suggest that keratocytes could promote the expression of VEGFr3 and MMP13, and CNV formation through PPARα downregulation. It was considered that FP/FM could be useful for long-term control of pediatric asthma.
- | Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) Containing Rice Bran Oil for Enhanced Fenofibrate Oral Delivery: In Vitro Digestion, Ex Vivo Permeability, and In Vivo Bioavailability Studies. (Pubmed Central) - Nov 12, 2020
On the other hand, the ex vivo permeability data of the predigested SNEDDS correlated well with the in vivo bioavailability data designating the superiority of rice bran oil with Kolliphor EL as the surfactant, to enhance the oral absorption of fenofibrate. Results indicated that valorization of agro-industrial waste such as rice bran oil may prove useful in enhancing the oral performance of LbDDS in the case of fenofibrate, while at the same time maximizing the use of agricultural by-products via the creation of new sustainable value chains in the pharmaceutical field.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Antiepileptic drug-activated constitutive androstane receptor inhibits peroxisome proliferator-activated receptor α- and peroxisome proliferator-activated receptor γ coactivator 1α-dependent gene expression to increase blood triglyceride levels. (Pubmed Central) - Nov 12, 2020
The increase in PPARα target gene expression induced by fenofibrate, a PPARα ligand, was inhibited by cotreatment with phenobarbital...Significance Statement CAR activated by antiepileptic drugs inhibits the PPARα-dependent transcription of genes related to lipid metabolism and upregulates blood TG levels. The molecular mechanism of this inhibition involves competition between these nuclear receptors for coactivator PGC1α binding.
- |||| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Become part of the dry eye digital dialogue with Alcon by going to https://t.co/w0j9ck6jbn to register! #Ad #Alcon, #SystaneiLux, #Expandyourpractice, #MGD, #RootCause, #DryEye, #iluviLux, #SeeBrilliantly, #DEEP #optometry #ophthalmology (Twitter) - Nov 11, 2020
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Case report of familial chylomicronemia syndrome, the most rare type of dyslipidemia (type I) () - Nov 9, 2020 - Abstract #ECP2020ECP_4865;
Furthermore,carotid ultrasound, as well as ultrasonography of the lower extremity veins and arteries showed not significant stenosis. and depth of eye in nature.Fundoscopy showed no abnormal findings.Genetic testing and checking of the lipidemic profile of the offspring of the patient was recommended.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Case report of familial chylomicronemia syndrome, the most rare type of dyslipidemia (type I) () - Nov 9, 2020 - Abstract #ECP2020ECP_3171;
Furthermore,carotid ultrasound, as well as ultrasonography of the lower extremity veins and arteries showed not significant stenosis. and depth of eye in nature.Fundoscopy showed no abnormal findings.Genetic testing and checking of the lipidemic profile of the offspring of the patient was recommended.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Case report of familial chylomicronemia syndrome, the most rare type of dyslipidemia (type I) () - Nov 9, 2020 - Abstract #ECP2020ECP_1497;
Furthermore,carotid ultrasound, as well as ultrasonography of the lower extremity veins and arteries showed not significant stenosis. and depth of eye in nature.Fundoscopy showed no abnormal findings.Genetic testing and checking of the lipidemic profile of the offspring of the patient was recommended.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal, Monotherapy: A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury. (Pubmed Central) - Nov 7, 2020
In the same comparison at Mo4, the treatment group maintained a 40% (±20%; p < 0.05) reduction in serum TG concentration, had an 18% in reduction in LDL-C (±12%; p < 0.05) and a 23% (±23%; p < 0.05) increase in HDL-C. Fenofibrate monotherapy for Mo2 and Mo4 initiated in persons with SCI resulted in a robust and favorable change in the serum lipoprotein profile and ratios, suggesting reduced risk for cardiovascular disease.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina. (Pubmed Central) - Nov 5, 2020
In addition, treatment of RPE cells with peroxisome proliferator-activated receptor (PPAR) α-agonist fenofibrate prevented iron-induced activation of oxidative stress and Wnt/β-catenin signaling by chelating the iron. The role of fenofibrate, an FDA-approved drug for hyperlipidemia, as an iron chelator has potentially significant therapeutic impact on iron associated degenerative diseases.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1. (Pubmed Central) - Nov 3, 2020
Most importantly, the cardioprotective effects of PPARα could be neutralized by knocking down MEOX1. In summary, PPARα plays a vital role in DOX-induced cardiotoxicity and is a promising treatment target.
- || Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Clinical, Journal: Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore. (Pubmed Central) - Nov 1, 2020
The use of fluticasone propionate/formoterol fumarate dihydrate (FP/FORM) pressurized metered-dose (pMDI, Flutiform), a type of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) fixed-dose combination, has been associated with lower oral corticosteroid-requiring exacerbation rates than other ICS/LABA fixed-dose combinations, fluticasone propionate/salmeterol xinafoate (FP/SAL) and budesonide/formoterol fumarate (BUD/FORM)...In the scenario where patients switched from BUD/FORM, greater drug (S$2,572,797) and exacerbation management (S$256,781) cost savings were observed over 5 years. The analysis provides a perspective that the increased access to FP/FORM could help achieve drug and exacerbation cost savings for the treatment of moderate-to-severe asthma.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Pathogenic Role of PPARα Down-Regulation in Corneal Nerve Degeneration and Impaired Corneal Sensitivity in Diabetes. (Pubmed Central) - Oct 27, 2020
Western blot analysis revealed significantly altered neurotrophic factor levels in diabetic rat corneas, which were partially restored by fenofibrate treatment. These results indicate that PPARα protects corneal nerve from degeneration induced by diabetes, and PPARα agonists have therapeutic potential in the treatment of diabetic keratopathy.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Satellite glial cells promote regenerative growth in sensory neurons. (Pubmed Central) - Oct 26, 2020
The PPARα agonist fenofibrate rescues the impaired axon regeneration in mice lacking Fasn in SGC. These results indicate that PPARα activity downstream of FASN in SGC contributes to promote axon regeneration in adult peripheral nerves and highlight that the sensory neuron and its surrounding glial coat form a functional unit that orchestrates nerve repair.
- || Triglide (fenofibrate) / Vectura, Shionogi
Review, Journal: PPARα Agonist Oral Therapy in Diabetic Retinopathy. (Pubmed Central) - Oct 26, 2020
Furthermore, oral administration of selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) agonists may induce hepatic fibroblast growth factor 21 expression, indirectly resulting in retinal protection in animal studies. Our review will enable more comprehensive approaches for understanding protective roles of PPARα for the prevention of DR development.
- | Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. (Pubmed Central) - Oct 24, 2020
Moreover, since fenofibrate is a FDA-approved drug that has an excellent safety profile, our findings suggest that fenofibrate could be a potential pharmacological therapy for GSD Ia in neonatal and pediatric patients as well as for adults. These findings also may apply to non-alcoholic fatty liver disease (NAFLD), which shares similar pathological and metabolic changes with GSD Ia.
- | Triglide (fenofibrate) / Vectura, Shionogi, Parmodia (pemafibrate) / Kowa
Journal: Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations. (Pubmed Central) - Oct 24, 2020
The structure also reveals that the conformation of the phenoxyalkyl group in pemafibrate is flexible in the absence of SRC1 coactivator peptide bound to PPARα; this gives a freedom for the phenoxyalkyl group to adopt structural changes induced by the binding of coactivators. FMO calculations have indicated that the accumulation of hydrophobic interactions provided by the residues at the LBP improve the interaction between pemafibrate and PPARα compared with the interaction between fenofibrate and PPARα.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Exercise as medicine for COVID-19: On PPAR with emerging pharmacotherapy. (Pubmed Central) - Oct 23, 2020
Herein, exercise will be compared to fenofibrate as a possible therapeutic strategy to bolster resilience against (and help manage recovery from) COVID-19. This paper will explore the hypothesis that exercise may be a useful adjuvant in a setting of COVID-19 management/rehabilitation due to its effects on PPARα and vascular endothelial function.
- | Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Phenolic-Rich Extract from Almond (Prunus dulcis) Hulls Improves Lipid Metabolism in Triton WR-1339 and High-Fat Diet-Induced Hyperlipidemic Mice and Prevents Lipoprotein Oxidation: A Comparison with Fenofibrate and Butylated Hydroxyanisole. (Pubmed Central) - Oct 23, 2020
The extract contains 342.63±3.44 mg/g total phenolics, 144.67±6.83 mg/g tannins, and 20.66±0.92 mg/g flavonoids. These finding indicate that almond hulls contain polar products able to lower plasma lipid concentrations and which might be beneficial for the treatment of hyperlipidemia and prevention of atherosclerosis.
- | Triglide (fenofibrate) / Vectura, Shionogi, Parmodia (pemafibrate) / Kowa
Journal: Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways. (Pubmed Central) - Oct 22, 2020
However, suppression by fenofibrate was not reversed by PPARα knockdown but by Sirtuin 1 (SIRT1) knockdown. In conclusion, pemafibrate and fenofibrate similarly suppresses microglial activation but through distinct PPARα and SIRT1-dependet pathways.
- || Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Clinical, Journal: Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. (Pubmed Central) - Oct 21, 2020
In conclusion, pemafibrate and fenofibrate similarly suppresses microglial activation but through distinct PPARα and SIRT1-dependet pathways. Fluticasone/salmeterol carried a higher risk of active TB compared with budesonide/formoterol among COPD patients.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: High-rate algal pond for removal of pharmaceutical compounds from urban domestic wastewater under tropical conditions. Case study: Santiago de Cali, Colombia. (Pubmed Central) - Oct 21, 2020
Fluticasone/salmeterol carried a higher risk of active TB compared with budesonide/formoterol among COPD patients. Removal efficiencies were high (>70%) for fenofibric acid, ibuprofen, and paracetamol; medium (30-70%) for gabapentin, lamotrigine, fenofibrate, gemfibrozil, diclofenac, ketoprofen, naproxen, and pentoxifylline; and low (50%) in the ecological hazard posed by most of the compounds, although it is important to note that the hazard from gemfibrozil and ibuprofen remained high even after treatment, indicating the need for complementary treatment.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Topical administration of 1% glycopyrronium bromide (GPB) cream is efficient and safe in treatment of primary axillary hyperhidrosis: A randomized placebo-controlled trial () - Oct 20, 2020 - Abstract #EADV2020EADV_2977;
- || Ventolin (albuterol) / GSK, Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi, Fostair (beclometasone/formoterol) / Chiesi
Clinical, Journal: Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. (Pubmed Central) - Oct 16, 2020
Switching to DPIs would result in large carbon savings and can be achieved alongside reduced drug costs by using less expensive brands. Substantial carbon savings can be made by using small volume HFA134a MDIs, in preference to large volume HFA134a MDIs, or those containing HFA227ea as a propellant.
- || Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Clinical, PK/PD data, Journal: Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects. (Pubmed Central) - Oct 16, 2020
BDP/FF/GB pMDI was safe and well tolerated in healthy Chinese subjects. The PK profiles were comparable to previously published data from Western European healthy Caucasian subjects.
- || Triglide (fenofibrate) / Vectura, Shionogi
Biomarker, Clinical, Journal: A Randomised Controlled Trial Assessing the Effects of Peri-operative Fenofibrate Administration on Abdominal Aortic Aneurysm Pathology: Outcomes From the FAME Trial. (Pubmed Central) - Oct 15, 2020
The PK profiles were comparable to previously published data from Western European healthy Caucasian subjects. A short course of 145 mg of fenofibrate/day did not lower concentrations of OPN or aortic macrophage density in people with large AAAs.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. (Pubmed Central) - Oct 15, 2020
Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] ETHNIC SENSITIVITY STUDY OF THE EXTRA-FINE SINGLE-INHALER TRIPLE THERAPY BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRRONIUM BROMIDE (BDP/FF/GB) PRESSURISED METERED DOSE INHALER (PMDI) IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2233;
These results are in line with available literature on exposure to these drugs in Japanese subjects. CLINICAL IMPLICATIONS: No dose adjustments in Japanese are deemed necessary for BDP/FF/GB pMDI.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
[VIRTUAL] CROSS-SECTIONAL SURVEY TO ASSESS COPD MEDICATION USE BY UNITED STATES PHYSICIANS () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2165;
Pulms were more likely to utilize dual bronchodilation than PCPs. PCPs were more likely to suggest ICS/LABA than Pulms.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
[VIRTUAL] REAL-WORLD PATTERNS AND IMPLICATIONS OF SHORT-ACTING BETA-AGONIST USE AMONG PATIENTS WITH COPD () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2148;
Additional management approaches for COPD may be needed to mitigate burden of disease. CLINICAL IMPLICATIONS: The proportion of patients with exacerbations was found to increase with increasing SABA use.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Efficacy of Double Filtration Plasmapheresis Therapy on Patients with Lipoprotein Glomerulopathy (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_2511;
Short-term efficacy of DFPP in patients with LPG was definite. However, Scr and ApoE levels rebounded in some patients during long-term follow-up
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Fibrates and CKD Patients: A Controversial Issue (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1054;
The long term effects of fibrates versus variable renal derangement are yet to be identified. As to lipid profile, shifting from fibrates to statins led to a stastically significant rise in triglycerides but it's clinical impact is yet to be investigated, so established guidelines might need a revision regarding clinical benefits of fibrates versus it's renal injury.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] PRURITUS IN PRIMARY BILIARY CHOLANGITIS IS UNDER-TREATED IN CLINICAL PRACTICE: RESULTS FROM TARGET-PBC () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1263;
Pruritus is under-treated in this real world PBC population and many patients with CS itch never receive treatment. TARGET-PBC is sponsored by TARGET PharmaSolutions; GSK provided funding for this analysis (213259).
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] LONG-TERM FENOFIBRATE TREATMENT IN BILE DUCT LOSS CAUSED BY DRUGS INDUCED LIVER DISEASE IMPROVES BIOCHEMISTRY () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1200;
TARGET-PBC is sponsored by TARGET PharmaSolutions; GSK provided funding for this analysis (213259). We suggest to use fenofibrate as an adjunct therapy while insensitive to conventional treatment in patients with VBDS caused by drugs, and should strictly monitored the biochemistry during therapy.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] FENOFIBRATE INCREASES BILE ACID GLUCURONIDATION TO REDUCE BILE ACID TOXICITY IN PATIENTS WITH PBC AND PSC WHO ARE PARTIAL RESPONDERS TO URSODIOL () - Oct 11, 2020 - Abstract #AASLD2020AASLD_101;
Increases in BA glucuronidation in patients with PBC and PSC receiving combination therapy with fenofibrate suggest that PPARα activation by fenofibrate detoxifys primary and secondary BAs by upregulating BA glucuronidation during cholestasis, to promote a less toxic bile acid pool. Fenofibrate is a promising treatment option for patients with PBC and PSC who experience a sub-therapeutic response to Ursodiol monotherapy.
- | Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal, IO Biomarker: Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro. (Pubmed Central) - Oct 11, 2020
A miRNA microarray revealed that fenofibrate differentially regulated cellular miRNAs with known roles in cancer and angiogenesis. The data raise the possibility that fenofibrate could be useful in angiosarcoma therapy, especially considering its well-established clinical safety and tolerability profile.
- | Triglide (fenofibrate) / Vectura, Shionogi, Lacromid (bezafibrate) / Remedica
Clinical, Journal: Additional fibrate treatment in UDCA-refractory PBC patients. (Pubmed Central) - Oct 11, 2020
The data raise the possibility that fenofibrate could be useful in angiosarcoma therapy, especially considering its well-established clinical safety and tolerability profile. In patients with UDCA-refractory PBC, additional fibrate treatment is associated with a higher probability of ALP normalization and a lower risk of cirrhosis development and hepatic deterioration.
- || Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study. (Pubmed Central) - Oct 11, 2020
In patients with UDCA-refractory PBC, additional fibrate treatment is associated with a higher probability of ALP normalization and a lower risk of cirrhosis development and hepatic deterioration. The results of the study indicate that macroprolactinaemia exerts a negative impact on cardiometabolic effects of fenofibrate.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fenofibrate Reverses Dysfunction of EPCs Caused by Chronic Heart Failure. (Pubmed Central) - Oct 10, 2020
Similar results were also found for tube formation and migration in late EPCs, which were significantly improved by fenofibrate in an AMPK-dependent manner (p < 0.05), suggesting that fenofibrate reversed CACs and late EPC dysfunction in CHF patients. The present findings reveal the potential application of the AMPK agonist fenofibrate to reverse endothelial dysfunction in CHF patients.
- Triglide (fenofibrate) / Vectura, Shionogi, Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient () - Oct 8, 2020 - Abstract #ASHP2020ASHP_342;
The patient was then transitioned to oral prednisone followed by a long taper over five weeks...This case report shows that life threatening cardiac adverse events in the form of myocarditis may occur with pembrolizumab use, warranting vigilant cardiac monitoring. Troponin monitoring in high risk patients, along with baseline TTE may help identify this complication in a timely manner to prevent life-threatening consequences.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. (Pubmed Central) - Oct 8, 2020
We validated that combined inhibition of ATM and treatment with fenofibrate is synergistic in multiple HGSOC cell lines by inducing senescence. Together, our results suggest that metabolic changes induced by ATM inhibitors are a potential target for the treatment of HGSOC.
- || Triglide (fenofibrate) / Vectura, Shionogi, Frumeron (indapamide) / Remedica
Clinical, Review, Journal: Drug treatments in patients with cardiac diseases and epilepsy. (Pubmed Central) - Oct 8, 2020
Together, our results suggest that metabolic changes induced by ATM inhibitors are a potential target for the treatment of HGSOC. Available data show that the treatment of patients with epilepsy and vascular comorbidities is challenging and requires the appropriate knowledge of pharmacological properties of drugs and drug interactions.
- | Triglide (fenofibrate) / Vectura, Shionogi
Journal: MiR-21 promotes calcium oxalate-induced renal tubular cell injury by targeting PPARA. (Pubmed Central) - Oct 8, 2020
Suppression of miR-21 by miRNA antagomiR or activation of PPAR-α by its selective agonist fenofibrate significantly reduced renal lipid accumulation and protected against renal injury in vivo...In situ hybridization of biopsy samples from patients with nephrocalcinosis revealed that miR-21 was also significantly upregulated compared with normal kidney tissues from patients with renal cell carcinoma who underwent radical nephrectomy. These results suggested that miR-21 promoted calcium oxalate-induced renal tubular cell injury by targeting PPARA, indicating that miR-21 could be a potential therapeutic target and biomarker for nephrolithiasis.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Trial initiation date: XPERTT: Investigating the Effects of QVM149 on MRI Ventilation Defects (clinicaltrials.gov) - Oct 5, 2020
P3, N=48, Not yet recruiting, Sponsor: Dr. Grace Parraga
These results suggested that miR-21 promoted calcium oxalate-induced renal tubular cell injury by targeting PPARA, indicating that miR-21 could be a potential therapeutic target and biomarker for nephrolithiasis. Initiation date: Sep 2020 --> Dec 2020
- Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei, Onbrez (indacaterol) / Novartis
[VIRTUAL] Cost-Utility Analysis of Fixed Dose Combination (FDC) of Indacaterol Acetate (IND) Glycopyrronium Bromide (GLY) and Mometasone Furoate (MF) As a Maintenance Treatment in Adult Asthma Patients not Adequately Controlled with a Maintenance Com ... () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_691;
ICUR results of €14,088. At a threshold of €20,000 per QALY, IND/GLY/MF has nearly 100% probability of being cost-effective.CONCLUSIONS : The results indicate that IND/GLY/MF is cost-effective among the considered comparisons in a representative cohort of adult asthma patients in Italy.
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] IMPACT of Generic Competition on Reference Price per DDD and Reimbursed Costs on Antihyperlipidemic Medicines () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_574;
The final costs of NHIF are affected not only by the differences in the reference price per DDD. The increasing utilization of newer and expensive medicines also impact the overall expenditure and market share of the products.
- Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] Cost-Effectiveness of Once-Daily Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_204;
The increasing utilization of newer and expensive medicines also impact the overall expenditure and market share of the products. At a willingness-to-pay threshold of $50,000/QALY, treatment with IND/GLY/MF is cost-effective in patients with uncontrolled moderate-to-severe asthma compared with SAL/FLU+Tio or SAL/FLU from a Canadian health care payer perspective.
- Veramyst (fluticasone furoate nasal spray) / GSK, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
[VIRTUAL] IMPACT of Health Technology Assessment (HTA) Recommendations on the Use of Fixed-Dose Combination (FDC) Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_195;
Initiatives aimed at restricting the use of FDC triple therapy leads to lower than average prescribing rates and potentially more appropriate use. It is essential for payers to assess the range of factors, including the risks and benefits of triple FDCs, and consider which restrictions would ensure the most efficient use of limited healthcare resources.